Successful informative session on U.S. Non-dilutive funding at IDIBELL


The “U.S. Federal sources for health Projects” informative session was successfully held at IDIBELL last October 21st. Jointly co-organized with AGAUR, the Agency for Management of University and Research Grants, the session featured two seminars on U.S. funding sources for Health Projects, that were delivered by Dr. Ana Turchetti-Maia, Director of Business Development at Freemind Consultants. 


With over tan 50 attendees from different institutions in the field of health of the Catalan research system, the session was opened by Dr. Capellá, Director of IDIBELL, who highlighted the potential of the American funding for European researchers in the biomedical field. Organizations such as the National Institutes of Health (NIH), the Department of Defense (DoD) or the Biomedical Advanced Research Development Authority (BARDA) can award funding to non-U.S. applicants. NIH, one of the most renowned funding bodies had a 39.1 USD billion for year 2019, of which roughly 31 billion are open to extramural applicants. From 2009 to 2018, Spanish universities and research institutes secured 7 million USD funding in NIH awards. 


The first seminar delivered by Dr. Turchetti, “Tips on how to prepare an application for US federal sources” provided a very hands-on approach on the practical aspects of the whole application procedure and the process on how to draft a grant application strategy. The second seminar, “US non-dilutive funding opportunities for Spanish academics” provided a highly informative overview of the federal funds landscape for health research in the United States.


The session was organized within the framework of the ICABELL Project, which is an initiative of IDIBELL that will contribute to enhance the international activity of the institute’s partners (Catalan Institute of Oncology, University Hospital of Bellvitge, University of Barcelona and Viladecans Hospital), whose research is managed at IDIBELL. 


IDIBELL’s mission is to promote and facilitate translational research of scientific excellence that integrates innovation and technology transfer in biomedicine, to achieve the continuous improvement of health and quality of life. In this context, it is expected that the actions carried out within the framework of this project will lead to a qualitative leap in quality and participation in international research projects.  

Scroll to Top